ASBrS Recommends IceCure’s Cryoablation for Low-Risk Breast Cancer Treatment

Key Facts

1The American Society of Breast Surgeons (ASBrS) updated its 2026 Resource Guide to recommend cryoablation as an option for low-risk early-stage breast cancer patients.

2The recommendation is based on IceCure's ICE3 study results and a favorable FDA Advisory Panel vote.

3The update is expected to accelerate commercial adoption of IceCure Medical's ProSense technology following FDA clearance.

The American Society of Breast Surgeons (ASBrS) has updated its 2026 Resource Guide to include cryoablation as a recommended treatment option for early-stage, low-risk breast cancer patients. This pivotal recommendation is supported by robust clinical data from IceCure Medical’s ICE3 study and a favorable benefit-risk assessment by an FDA Advisory Panel. The inclusion in these clinical guidelines is expected to significantly accelerate the commercial adoption of IceCure’s ProSense technology following official FDA clearance. Industry analysts suggest that this milestone will facilitate insurance reimbursement and drive broader adoption among surgical professionals globally. For IceCure Medical (Nasdaq: ICCM), this development represents a major catalyst for long-term revenue growth and market penetration in the oncology sector. The move underscores a shift toward minimally invasive solutions in breast cancer management.